Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Gross Margin (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Gross Margin for 15 consecutive years, with 98.25% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin fell 22.0% year-over-year to 98.25%; the TTM value through Mar 2026 reached 98.25%, down 18.0%, while the annual FY2025 figure was 98.3%, 9.0% down from the prior year.
  • Gross Margin hit 98.25% in Q1 2026 for Corcept Therapeutics, roughly flat from 98.74% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.74% in Q4 2025 and bottomed at 97.79% in Q3 2025.
  • Average Gross Margin over 5 years is 98.49%, with a median of 98.56% recorded in 2022.
  • On a YoY basis, Gross Margin climbed as much as 37bps in 2025 and fell as far as -64bps in 2025.
  • Corcept Therapeutics' Gross Margin stood at 98.56% in 2022, then rose by 0bps to 98.61% in 2023, then decreased by 0bps to 98.37% in 2024, then rose by 0bps to 98.74% in 2025, then fell by 0bps to 98.25% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 98.25%, 98.74%, and 97.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.